These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 20042515

  • 1. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.
    Su YJ, Tsai MS, Kuo YH, Chiu YF, Cheng CM, Lin ST, Lin YW.
    Mol Pharmacol; 2010 Apr; 77(4):633-43. PubMed ID: 20042515
    [Abstract] [Full Text] [Related]

  • 2. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.
    Ko JC, Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.
    Toxicol Appl Pharmacol; 2011 Sep 15; 255(3):327-38. PubMed ID: 21810436
    [Abstract] [Full Text] [Related]

  • 3. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC, Ciou SC, Cheng CM, Wang LH, Hong JH, Jheng MY, Ling ST, Lin YW.
    Carcinogenesis; 2008 Jul 15; 29(7):1448-58. PubMed ID: 18544565
    [Abstract] [Full Text] [Related]

  • 4. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
    Ko JC, Tsai MS, Kuo YH, Chiu YF, Weng SH, Su YC, Lin YW.
    Biochem Pharmacol; 2011 Mar 01; 81(5):680-90. PubMed ID: 21168393
    [Abstract] [Full Text] [Related]

  • 5. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.
    Lung Cancer; 2010 Aug 01; 69(2):155-64. PubMed ID: 19962780
    [Abstract] [Full Text] [Related]

  • 6. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
    Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, Lin YW.
    Exp Cell Res; 2009 Sep 10; 315(15):2658-72. PubMed ID: 19505457
    [Abstract] [Full Text] [Related]

  • 7. Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.
    Ko JC, Wang TJ, Chang PY, Syu JJ, Chen JC, Chen CY, Jian YT, Jian YJ, Zheng HY, Chen WC, Lin YW.
    Biochem Pharmacol; 2015 Oct 01; 97(3):331-40. PubMed ID: 26212550
    [Abstract] [Full Text] [Related]

  • 8. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells.
    Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Lin YW.
    Biochem Pharmacol; 2010 Feb 15; 79(4):655-64. PubMed ID: 19799875
    [Abstract] [Full Text] [Related]

  • 9. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
    Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, Lin ST, Chang CC, Lin YW.
    Mol Cancer Res; 2009 Aug 15; 7(8):1378-89. PubMed ID: 19671683
    [Abstract] [Full Text] [Related]

  • 10. The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
    Ko JC, Hong JH, Wang LH, Lin YW.
    Exp Cell Res; 2008 May 01; 314(8):1881-91. PubMed ID: 18377894
    [Abstract] [Full Text] [Related]

  • 11. Induction of Rad51 protein levels by p38 MAPK decreases cytotoxicity and mutagenicity in benzo[a]pyrene-exposed human lung cancer cells.
    Chuang SM, Wang LH, Hong JH, Lin YW.
    Toxicol Appl Pharmacol; 2008 Aug 01; 230(3):290-7. PubMed ID: 18430445
    [Abstract] [Full Text] [Related]

  • 12. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.
    Regul Toxicol Pharmacol; 2012 Dec 01; 64(3):415-24. PubMed ID: 23069143
    [Abstract] [Full Text] [Related]

  • 13. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
    Ko JC, Tsai MS, Chiu YF, Weng SH, Kuo YH, Lin YW.
    J Pharmacol Exp Ther; 2011 Jul 01; 338(1):184-94. PubMed ID: 21444628
    [Abstract] [Full Text] [Related]

  • 14. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.
    Ko JC, Chen JC, Wang TJ, Zheng HY, Chen WC, Chang PY, Lin YW.
    Biochem Pharmacol; 2016 Apr 01; 105():91-100. PubMed ID: 26921637
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of mitomycin C-induced cytotoxicity by curcumin results from down-regulation of MKK1/2-ERK1/2-mediated thymidine phosphorylase expression.
    Weng SH, Tsai MS, Chiu YF, Kuo YH, Chen HJ, Lin YW.
    Basic Clin Pharmacol Toxicol; 2012 Mar 01; 110(3):298-306. PubMed ID: 21973306
    [Abstract] [Full Text] [Related]

  • 16. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
    Ko JC, Wang LH, Jhan JY, Ciou SC, Hong JH, Lin ST, Lin YW.
    Lung Cancer; 2009 Sep 01; 65(3):290-8. PubMed ID: 19157634
    [Abstract] [Full Text] [Related]

  • 17. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.
    Ko JC, Hong JH, Wang LH, Cheng CM, Ciou SC, Lin ST, Jheng MY, Lin YW.
    Mol Cancer Ther; 2008 Nov 01; 7(11):3632-41. PubMed ID: 19001445
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.
    Mol Cancer Res; 2007 May 01; 5(5):509-20. PubMed ID: 17510316
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.